Onconaut Therapeutics

Onconaut Therapeutics is a private, preclinical biotech startup pioneering a novel approach to oncology by targeting the CHD1L oncogene, a driver of aggressive tumor behavior and therapy resistance. The company is advancing a series of small molecule inhibitors through IND-enabling studies, with an initial focus on cancers such as liver, breast, lung, and colon where CHD1L overexpression correlates with poor outcomes. Leveraging foundational academic research, Onconaut's strategy is to develop best-in-class therapies that enhance the efficacy of current treatments and reduce recurrence risk. As a pre-revenue entity, its near-term goal is to achieve clinical validation of its lead candidates.

Platform for the discovery and development of small molecule inhibitors targeting the CHD1L oncogene to block cancer progression, metastasis, and drug resistance.

There are no known clinical-stage competitors directly targeting CHD1L, giving Onconaut a potential first-mover advantage. However, it competes indirectly with numerous companies developing therapies for the same cancer indications and targeting other mechanisms of resistance. The landscape is intensely competitive, requiring superior clinical data to secure market position.